ライフサイエンスコーパス: neuroendocrine tumor

1 l examination revealed a primary gallbladder neuroendocrine tumor.

2 had a hepatic metastasis from a small-bowel neuroendocrine tumor.

3 agon-expressing microadenomas (3 of 8) and a neuroendocrine tumor.

4 phaga species in a patient with a metastatic neuroendocrine tumor.

5 ding one advanced PDAC and one early grade 2 neuroendocrine tumor.

6 C) is a rare but highly aggressive cutaneous neuroendocrine tumor.

7 tivation of beta-catenin was observed in the neuroendocrine tumors.

8 on the intended management of patients with neuroendocrine tumors.

9 the impact of DOTATATE on the management of neuroendocrine tumors.

10 is a treatment for inoperable or metastatic neuroendocrine tumors.

11 d improve the availability of PET imaging of neuroendocrine tumors.

12 derivatives for the detection and staging of neuroendocrine tumors.

13 led receptor (GPCR) that is overexpressed in neuroendocrine tumors.

14 as are infrequent, genetically heterogeneous neuroendocrine tumors.

15 in receptors (SSTRs) in patients affected by neuroendocrine tumors.

16 radiopharmaceutical used for the therapy of neuroendocrine tumors.

17 re performed in 203 patients with metastatic neuroendocrine tumors.

18 targets may be adverse prognostic factors in neuroendocrine tumors.

19 PRRT with (177)Lu-octreotate for metastatic neuroendocrine tumors.

20 plasia with the potential for evolution into neuroendocrine tumors.

21 tions in patients with liver metastases from neuroendocrine tumors.

22 node metastases in patients with pancreatic neuroendocrine tumors.

23 ((18)F-FDOPA) PET, a new diagnostic tool for neuroendocrine tumors.

24 e examined whether sst2 is phosphorylated in neuroendocrine tumors.

25 nesis and treatment of poorly differentiated neuroendocrine tumors.

26 is targeted by the SS analogs used to treat neuroendocrine tumors.

27 lioma, multiple endocrine neoplasia IIB, and neuroendocrine tumors.

28 e imaging modality of choice for identifying neuroendocrine tumors.

29 efficacy of this treatment regimen in human neuroendocrine tumors.

30 8)Ga-DOTATATE uptake and histologic grade of neuroendocrine tumors.

31 and one minor response in two patients with neuroendocrine tumors.

32 osis, prognosis, and treatment of pancreatic neuroendocrine tumors.

33 n the diagnosis and management of pancreatic neuroendocrine tumors.

34 year in EUS in the evaluation of pancreatic neuroendocrine tumors.

35 interventions in the treatment of pancreatic neuroendocrine tumors.

36 EUS in the clinical management of pancreatic neuroendocrine tumors.

37 ted cancer gene therapy for the treatment of neuroendocrine tumors.

38 a differential effect on known Rb-associated neuroendocrine tumors.

39 pancreas as well as in medulloblastomas and neuroendocrine tumors.

40 nts with advanced low- to intermediate-grade neuroendocrine tumors.

41 as were genes encoding signature proteins of neuroendocrine tumors.

42 mprise the majority of functional pancreatic neuroendocrine tumors.

43 i-institutional investigations on pancreatic neuroendocrine tumors.

44 s an important role in staging and restaging neuroendocrine tumors.

45 tide LAR among patients with advanced midgut neuroendocrine tumors.

46 and peptide receptor radionuclide therapy of neuroendocrine tumors.

47 ependent prognostic biomarkers of pancreatic neuroendocrine tumors.

48 tion of SQCC) shared molecular features with neuroendocrine tumors.

49 ssive, somatostatin-receptor-positive midgut neuroendocrine tumors.

50 ors may be useful as a potential therapy for neuroendocrine tumors.

51 g is a widely accepted method for imaging of neuroendocrine tumors.

52 uspected pulmonary or gastroenteropancreatic neuroendocrine tumors.

53 d in the clinic for imaging and treatment of neuroendocrine tumors.

54 in 728 patients with confirmed or suspected neuroendocrine tumors.

55 ging of pulmonary and gastroenteropancreatic neuroendocrine tumors.

56 dder are very rare, representing 0.2% of all neuroendocrine tumors.

57 increasingly used for managing patients with neuroendocrine tumors.

58 tide receptor radionuclide therapy (PRRT) of neuroendocrine tumors.

59 in 24 patients with hepatic metastases from neuroendocrine tumors (13 men, 11 women; mean age, 59.8

60 view of 31 patients with advanced metastatic neuroendocrine tumors (20 with carcinoid tumors and 11 w

61 l pancreatectomies were performed mainly for neuroendocrine tumors (35%), intraductal papillary mucin

62 eptide into the clinical setting to diagnose neuroendocrine tumors about 25 y ago, many advances have

63 From a prospective database of pancreatic neuroendocrine tumors, all patients with liver metastati

64 onducted in mantle cell lymphoma, pancreatic neuroendocrine tumors and astrocytomas.

65 clude renal carcinomas and cysts, pancreatic neuroendocrine tumors and cysts, pheochromocytomas, and

66 The present review provides an overview on neuroendocrine tumors and focuses on general features an

67 e summarizes recent advances in the field of neuroendocrine tumors and places them into context for b

68 port the use of certain radiolabeled AAs for neuroendocrine tumors and prostate cancer.

69 and peptide receptor radionuclide therapy of neuroendocrine tumors and provide successful imaging and

70 pancreatic ductal adenocarcinoma as well as neuroendocrine tumors and rarer subtypes of cancers of t

71 atients with progressive advanced pancreatic neuroendocrine tumors and was associated with a low rate

72 iately differentiated to well-differentiated neuroendocrine tumors and who underwent (68)Ga-DOTATATE

73 h colorectal tumors, 776 days for those with neuroendocrine tumors, and 207 days for those with nonco

74 al adenocarcinoma, sarcomatoid carcinoma and neuroendocrine tumors, and all died within 65 weeks.

75 , these results have been obtained mostly in neuroendocrine tumors, and only limited data are availab

76 ide therapy in the therapeutic algorithm for neuroendocrine tumors; and establish the basis for appro

77 Neuroendocrine tumors are a group of biologically and cl

78 Prognostic biomarkers for the pancreatic neuroendocrine tumors are needed.

79 Pancreatic neuroendocrine tumors are rare neoplasms often associate

80 domized trials of sunitinib in patients with neuroendocrine tumors are warranted.

81 c radionuclide approach to the management of neuroendocrine tumors, as described by the inventor of t

82 y was to characterize and classify pulmonary neuroendocrine tumors based on array comparative genomic

83 are serotonin-secreting well-differentiated neuroendocrine tumors believed to originate from enteroc

84 l papillary mucinous neoplasm and pancreatic neuroendocrine tumor biology affect patient outcomes and

85 ound on many human cancers, most classically neuroendocrine tumors but also others.

86 , WaGa and Mkl-1 cells were similar to other neuroendocrine tumors, but the variant cell lines were n

87 nomenclatures have been proposed to stratify neuroendocrine tumors, but the World Health Organization

88 ing IFNgamma and/or TNFalpha into pancreatic neuroendocrine tumors can alleviate immune suppression.

89 nce from sequencing indicates that, although neuroendocrine tumors can arise de novo, they can also d

90 Gastrinomas are rare functional neuroendocrine tumors causing the Zollinger-Ellison synd

91 lation experiments with the human pancreatic neuroendocrine tumor cell line BON-1 were performed at b

92 iodobenzylguanidine ((131)I-MIBG) therapy of neuroendocrine tumors comprises different dosing schemes

93 Paragangliomas are benign neuroendocrine tumors derived from the glomus cells of t

94 e imaging properties in an in vivo model for neuroendocrine tumors, despite the fact that the injecte

95 treatment at an academic institution, and a neuroendocrine tumor diagnosis (all P < 0.01).

96 ation and advancements concerning pancreatic neuroendocrine tumor diagnosis, imaging characteristics,

97 in the clinical evaluation and management of neuroendocrine tumors, especially in neuroblastoma, para

98 rrently a mainstay in the evaluation of many neuroendocrine tumors, especially neuroblastoma.

99 s a useful tool for the detection of certain neuroendocrine tumors, especially with the preadministra

100 tidisciplinary consensus panel consisting of neuroendocrine tumor experts, including oncologists, gas

101 le might be advantageous for imaging because neuroendocrine tumors express different subtypes of soma

102 Neuroendocrine tumors express vascular endothelial growt

103 ted sst2 is present in most gastrointestinal neuroendocrine tumors from patients treated with octreot

104 ses for patients with gastroenteropancreatic neuroendocrine tumors (GEP NET) after peptide receptor r

105 Gastroenteropancreatic neuroendocrine tumors (GEP NETs) are relatively rare neo

106 ignant melanoma (MM), gastroenteropancreatic neuroendocrine tumors (GEP NETs), and prostate cancer (P

107 TATE in patients with gastroenteropancreatic neuroendocrine tumors (GEP NETs).

108 arned a major role in gastroenteropancreatic neuroendocrine tumors (GEP NETs).

109 he same patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs) and to evaluate the cli

110 Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are a heterogeneous gro

111 eir perceived rarity, gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are rising in incidence

112 Gastro-entero-pancreatic neuroendocrine tumors (GEPNETs) are increasing in incide

113 Gastroenteropancreatic neuroendocrine tumors (GEPNETs) are indolent neoplasms p

114 ients with metastatic gastroenteropancreatic neuroendocrine tumors (GEPNETs).

115 ) is a promising treatment for patients with neuroendocrine tumors, giving rise to improved survival.

116 d among patients with early-stage pancreatic neuroendocrine tumors has not been well established.

117 Gastroenteropancreatic neuroendocrine tumors have occasionally been described i

118 ach (8%) and colon cancer, multiple myeloma, neuroendocrine tumor, head and neck squamous cell carcin

119 ms associated with hormone hypersecretion in neuroendocrine tumors; however, data on their antitumor

120 n human tumors, including cognate pancreatic neuroendocrine tumors, implying a generality.

121 ing the early-stage detection of a secondary neuroendocrine tumor in a patient with a known mutation

122 currently under evaluation against carcinoid/neuroendocrine tumors in a phase II clinical trial.

123 eatic endocrine tumors with small intestinal neuroendocrine tumors in clinical studies.

124 h cancer cells and macrophages in pancreatic neuroendocrine tumors in humans and mice.

125 The diagnosis of neuroendocrine tumors in particular has been a prime exa

126 egulated in lymphatics in or near pancreatic neuroendocrine tumors in RIP-Tag2 transgenic mice and wh

127 ctivity in patients with advanced pancreatic neuroendocrine tumors, in two phase 2 studies.

128 Neuroendocrine tumor incidence, prevalence, and OS rates

129 nificance of specific proteins in pancreatic neuroendocrine tumors including insulinoma.

130 etinoblastoma, a tumor of neural origin, and neuroendocrine tumors including small cell lung cancer a

131 CN is a driver mutation in a subset of human neuroendocrine tumors, including neuroblastoma.

132 iods of disease control in a wide variety of neuroendocrine tumors involving the pancreas.

133 5HTP) whose excellent in vivo performance in neuroendocrine tumors is mainly attributed to its decarb

134 tin receptor, which is overexpressed by many neuroendocrine tumors, is a well-known target for molecu

135 Serum chromogranin A, a marker for neuroendocrine tumors, is elevated in patients taking pr

136 nitinib has antitumor activity in pancreatic neuroendocrine tumors; its activity against carcinoid tu

137 diolabeled targeted therapy in patients with neuroendocrine tumors liver metastases; a lower pretreat

138 Medullary thyroid carcinoma (MTC) is a neuroendocrine tumor mainly caused by mutations in the r

139 ve tumors do not express pRb and express the neuroendocrine tumor markers synaptophysin and microtubu

140 Notch1 activation with VPA suppressed 2 neuroendocrine tumor markers, ASCL1 and chromogranin A.

141 easure levels of Notch1 pathway proteins and neuroendocrine tumor markers.

142 t in patients with liver-dominant metastatic neuroendocrine tumors (mNETs), despite the absence of le

143 h- and low-specific-activity (18)F-DOPA in a neuroendocrine tumor model to determine whether this dif

144 sin B (CtsB) and CtsS in a murine pancreatic neuroendocrine tumor model.

145 in a preclinical in vivo model of endogenous neuroendocrine tumors (multiple endocrine neoplasia [MEN

146 nancies (colorectal cancer [n = 195, 38.8%], neuroendocrine tumors [n = 77, 15.3%], breast cancer [n

147 oversy remains over whether small pancreatic neuroendocrine tumors need to be surgically resected or

148 e kinase; MTOR) pathway in the regulation of neuroendocrine tumor (NET) growth.

149 ectively assessed a consecutive cohort of 23 neuroendocrine tumor (NET) patients with liver-dominant

150 is widely used for guiding the management of neuroendocrine tumor (NET) patients.

151 established treatment exists for pancreatic neuroendocrine tumor (NET) progression after failure of

152 Mechanisms of neuroendocrine tumor (NET) proliferation are poorly unde

153 ncy ablation are used for hepatic metastatic neuroendocrine tumor (NET) therapy.

154 rgical treatment of patients presenting with neuroendocrine tumor (NET) with metastases.

155 gnosis, follow-up, and treatment planning of neuroendocrine tumor (NET).

156 s, and emerging anatomic modalities to stage neuroendocrine tumor (NET).

157 TATE PET/CT interpretations in patients with neuroendocrine tumor (NET).

158 months in patients with advanced pancreatic neuroendocrine tumors (NET) compared with placebo in the

159 The incidence of neuroendocrine tumors (NET) has increased dramatically i

160 antation (LT) for liver metastases (LM) from neuroendocrine tumors (NET) over a 27-year period.

161 The application of this beta- RGS to neuroendocrine tumors (NET) requires study of the uptake

162 are highly expressed in well-differentiated neuroendocrine tumors (NET).

163 had colorectal cancer (CRC; n = 195, 38.8%), neuroendocrine tumors (NET; n = 77, 15.3%), mammary canc

164 In neuroendocrine tumors, NET can be targeted for imaging a

165 IMS: Survival times vary among patients with neuroendocrine tumors (NETs) - even among those with the

166 Neuroendocrine tumors (NETs) are a complex group of mali

167 PURPOSE Neuroendocrine tumors (NETs) are considered rare tumors

168 Pancreatic neuroendocrine tumors (NETs) are rare neoplasms for whic

169 The incidence and prevalence of neuroendocrine tumors (NETs) are thought to be rising, b

170 Thymic neuroendocrine tumors (NETs) are uncommon but malignant

171 Neuroendocrine tumors (NETs) are uncommon tumors with in

172 Neuroendocrine tumors (NETs) arise from a variety of ana

173 Neuroendocrine tumors (NETs) can be treated by peptide r

174 Neuroendocrine tumors (NETs) can be visualized using rad

175 Neuroendocrine tumors (NETs) comprise a heterogeneous gr

176 st TNM staging classification for pancreatic neuroendocrine tumors (NETs) derived from the staging al

177 ECT have been used for functional imaging of neuroendocrine tumors (NETs) for the last 2 decades.

178 Metastatic gastrointestinal neuroendocrine tumors (NETs) frequently are refractory t

179 Small intestinal (SI) neuroendocrine tumors (NETs) have heterogeneous outcomes

180 s with inoperable or unresectable pancreatic neuroendocrine tumors (NETs) have limited treatment opti

181 on in management of patients with metastatic neuroendocrine tumors (NETs) is controversial.

182 retin receptor family, overexpressed on many neuroendocrine tumors (NETs) is of great importance beca

183 ne ((18)F-FDOPA) PET/CT in detecting primary neuroendocrine tumors (NETs) occult on morphologic and f

184 A high proportion of gut and bronchial neuroendocrine tumors (NETs) overexpresses somatostatin

185 Purpose Treatment options for neuroendocrine tumors (NETs) remain limited.

186 sst2) antagonists are better tools to target neuroendocrine tumors (NETs) than sst2 agonists.

187 ate ((18)F-FET-betaAG-TOCA) in patients with neuroendocrine tumors (NETs) to evaluate biodistribution

188 ; range, 20-90 y) with histologically proven neuroendocrine tumors (NETs) underwent both (68)Ga-DOTAT

189 udy, 176 patients with measurable metastatic neuroendocrine tumors (NETs) were recruited.

190 The molecular imaging and treatment of neuroendocrine tumors (NETs) with radiolabeled somatosta

191 iagnosis of somatostatin receptor-expressing neuroendocrine tumors (NETs), and SUV measurements are s

192 l to the diagnosis of gastroenteropancreatic neuroendocrine tumors (NETs), but detection rates, espec

193 In the treatment of neuroendocrine tumors (NETs), complete surgical removal

194 atients with suspected but yet not localized neuroendocrine tumors (NETs), early diagnosis or reliabl

195 to development and maintenance of pancreatic neuroendocrine tumors (NETs), with special reference to

196 sion-free survival in patients with advanced neuroendocrine tumors (NETs).

197 tment of gastroenteropancreatic and thoracic neuroendocrine tumors (NETs).

198 ng classification for jejunal-ileal (midgut) neuroendocrine tumors (NETs).

199 y in Europe over the past decade for imaging neuroendocrine tumors (NETs).

200 ts perform better than agonists in detecting neuroendocrine tumors (NETs).

201 ts with gastroenteropancreatic and bronchial neuroendocrine tumors (NETs).

202 y targeting VEGF, have antitumor activity in neuroendocrine tumors (NETs).

203 Ga-DOTATATE PET/CT on managing patients with neuroendocrine tumors (NETs).

204 macokinetics, and dosimetry of (18)F-MFBG in neuroendocrine tumors (NETs).

205 )In-DOTATATE) of patients with meningioma or neuroendocrine tumors (NETs).

206 use mortality after radiopeptide therapy for neuroendocrine tumors (NETs).

207 essed from planar images in 29 patients with neuroendocrine tumors (NETs; n = 21) or meningioma (n =

208 he pathogenesis of gastrinoma and pancreatic neuroendocrine tumors, new prognostic classification sys

209 Nonfunctioning pancreatic neuroendocrine tumors (NF-PanNETs) are often indolent ne

210 Patients with nonfunctional pancreatic neuroendocrine tumors (NF-PNETs) have poorer survival th

211 ated antigen otherwise found in melanoma and neuroendocrine tumors; normal expression is largely rest

212 horylated at Ser341/343 in receptor-positive neuroendocrine tumors obtained from 10 octreotide-treate

213 the urinary bladder is a rare and aggressive neuroendocrine tumor of the urinary bladder.

214 nfunctioning, somatostatin receptor-positive neuroendocrine tumors of grade 1 or 2 (a tumor prolifera

215 ng patients with metastatic enteropancreatic neuroendocrine tumors of grade 1 or 2 (Ki-67 <10%).

216 The primary neuroendocrine tumors of the gallbladder are very rare,

217 Neuroendocrine tumors of the pancreas are a heterogeneou

218 ns the most advisable therapy for resectable neuroendocrine tumors of the pancreas, there have been s

219 giocarcinoma, or other metastases (including neuroendocrine tumors or sarcomas) continued to recur an

220 y neoplasms, cystic variations of pancreatic neuroendocrine tumors, pancreatic ductal adenocarcinomas

221 modulated by PDGF-DD signaling in pancreatic neuroendocrine tumors (PanNET).

222 , its specific functions in human pancreatic neuroendocrine tumors (PanNETs) and spontaneous mouse mo

223 Pancreatic neuroendocrine tumors (PanNETs) are a rare but clinicall

224 Pancreatic neuroendocrine tumors (PanNETs) are a relatively rare bu

225 Pancreatic neuroendocrine tumors (PanNETs) are a type of pancreatic

226 Efforts to model human pancreatic neuroendocrine tumors (PanNETs) in animals have been mod

227 f these genes are common in human pancreatic neuroendocrine tumors (PanNETs), we examined the telomer

228 iagnosis and management of a wide variety of neuroendocrine tumors, particularly carcinoid.

229 Neuroendocrine tumors, particularly small intestinal tum

230 mor progression was 7.7 months in pancreatic neuroendocrine tumor patients and 10.2 months in carcino

231 e-year survival rate was 81.1% in pancreatic neuroendocrine tumor patients and 83.4% in carcinoid pat

232 ed on tumor cells is successfully applied in neuroendocrine tumor patients.

233 I study of advanced carcinoid and pancreatic neuroendocrine tumor patients.

234 motherapy has limited efficacy in metastatic neuroendocrine tumor patients.

235 Serum markers include chromogranin A for neuroendocrine tumors, pepsinogen I for gastric atrophy,

236 -hydroxycholesterol (24S-HC) in a pancreatic neuroendocrine tumor (pNET) model commonly used to study

237 s tumor burden was reduced in the pancreatic neuroendocrine tumor (PNET) model, the latter results co

238 rognostic factor in patients with pancreatic neuroendocrine tumor (pNET).

239 ckground develop both noninvasive pancreatic neuroendocrine tumors (PNET) and invasive carcinomas wit

240 Pancreatic neuroendocrine tumors (PNET) have a poorly defined natur

241 Pancreatic neuroendocrine tumors (pNET), also known as islet cell t

242 Pancreatic neuroendocrine tumors (pNETs) are a rare and heterogeneo

243 Sporadic pancreatic neuroendocrine tumors (pNETs) are rare and genetically h

244 Pancreatic neuroendocrine tumors (PNETs) are rare tumors, with an i

245 Management of pancreatic neuroendocrine tumors (PNETs) associated with von Hippel

246 osine inhibitor sunitinib in both pancreatic neuroendocrine tumors (PNETs) in RIP-Tag2 mice and cervi

247 Pancreatic neuroendocrine tumors (PNETs) may evolve and cause hormo

248 Pancreatic neuroendocrine tumors (PNETs), although rare, often meta

249 e are few effective therapies for pancreatic neuroendocrine tumors (PNETs).

250 ade and liver metastasis in human pancreatic neuroendocrine tumors (PNETs).

251 is significantly downregulated in pancreatic neuroendocrine tumors (PNETs).

252 in a family with hereditary paraganglioma, a neuroendocrine tumor previously linked to mutations in g

253 Neuroendocrine tumors (previously referred to as carcino

254 colorectal cancer (r = 0.2; P < 0.001), and neuroendocrine tumors (r = 0.2; P < 0.01).

255 The diagnosis of neuroendocrine tumor relies on clinical manifestation, l

256 highly angiogenic mouse model of pancreatic neuroendocrine tumor RIP-Tag2.

257 emic circulation from metastatic small bowel neuroendocrine tumors (SB NET) causes CS.

258 Though a rare entity, primary neuroendocrine tumor should be considered in the differe

259 tment of well differentiated small intestine neuroendocrine tumors (SI-NET).

260 Small intestinal neuroendocrine tumors (SI-NETs) are serotonin-secreting

261 Small intestine neuroendocrine tumors (SI-NETs) are the most common mali

262 The diagnosed incidence of small intestine neuroendocrine tumors (SI-NETs) is increasing, and the u

263 ng way in our understanding and treatment of neuroendocrine tumors since the term "karzinoide" was co

264 oint Committee on Cancer (AJCC) and European Neuroendocrine Tumor Society (ENETS) are prognostic for

265 idental diagnosis, and TNM staging (European Neuroendocrine Tumors Society [ENETS] v AJCC) using log-

266 of benefit in the ongoing RAD001 In Advanced Neuroendocrine Tumors study (RADIANT-4).

267 MEN1 mutations frequently cause neuroendocrine tumors such as gastrinomas, characterized

268 asL and hTERT in several particular types of neuroendocrine tumors such as pheochromocytomas, paragan

269 heranostics; review its current role in some neuroendocrine tumors, such as neuroblastoma, paragangli

270 atostatin analogues, which are used to treat neuroendocrine tumors, target the high levels of somatos

271 in RIP-Tag2 transgenic mice with pancreatic neuroendocrine tumors that developed spontaneously and p

272 Paragangliomas are rare neuroendocrine tumors that may arise anywhere along the

273 e most common type of functioning pancreatic neuroendocrine tumors that occur sporadically or as a pa

274 o had well-differentiated, metastatic midgut neuroendocrine tumors to receive either (177)Lu-Dotatate

275 he dose-response relationship for pancreatic neuroendocrine tumors treated with PRRT using (177)Lu-DO

276 in 24 patients with metastasized pancreatic neuroendocrine tumors treated with repeated cycles of (1

277 a treated with (131)I-tositumomab; case 2, a neuroendocrine tumor treatment simulated with (177)Lu-pe

278 Sixty consecutive patients with neuroendocrine tumors underwent both (68)Ga-DOTATOC and

279 pective setup, 14 patients with a history of neuroendocrine tumors underwent both PET/CT with (64)Cu-

280 Ten patients with metastatic neuroendocrine tumors underwent one 45-min dynamic and 3

281 Twenty patients with liver metastases from neuroendocrine tumors underwent T1-weighted DCE MR imagi

282 raphy, we demonstrated that-for instance, in neuroendocrine tumors-up to 3 receptors can be coexpress

283 curing early-stage disease while preventing neuroendocrine tumors using c-Kit-targeted therapy.

284 therapy of somatostatin receptor-expressing neuroendocrine tumors using somatostatin receptor radiol

285 of UCH-L1 and alpha-internexin in pancreatic neuroendocrine tumors was significantly associated with

286 l reported 2 female patients with pancreatic neuroendocrine tumors, WDS, and achlorhydria.

287 In 4 consecutive patients with advanced neuroendocrine tumors, we evaluated whether treatment wi

288 ty and use of DOTA analogs in the therapy of neuroendocrine tumors, we expect that (68)Ga-DOTATATE PE

289 Ten patients diagnosed with neuroendocrine tumors were included.

290 with a histologically confirmed diagnosis of neuroendocrine tumors were included.

291 Patients with advanced midgut neuroendocrine tumors who have had disease progression d

292 consecutive patients with known or suspected neuroendocrine tumors, who were evaluated with DOTATATE.

293 Small-cell lung cancer (SCLC), an aggressive neuroendocrine tumor with early dissemination and dismal

294 l carcinoma (MCC) is an aggressive cutaneous neuroendocrine tumor with high mortality rates.

295 Two hundred patients with metastatic neuroendocrine tumors with high somatostatin receptor ex

296 omatostatin analogs for in vivo diagnosis of neuroendocrine tumors with PET.

297 Treatment of neuroendocrine tumors with radiolabeled sst antagonists

298 , low-grade or intermediate-grade pancreatic neuroendocrine tumors with radiologic progression within

299 t 27, 29, and 34 months) and 4 node-positive neuroendocrine tumors (with 1 hepatic recurrence at 66 m

300 ave shown promising results in patients with neuroendocrine tumors, with a higher lesion detection ra